Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
about
The clinical effectiveness of intra-articular corticosteroids for arthritis of the lower limb in juvenile idiopathic arthritis: a systematic reviewTreatment of juvenile idiopathic arthritis: a revolution in careWhat does an adult rheumatologist need to know about juvenile idiopathic arthritis?Juvenile Idiopathic Arthritis: Diagnosis and TreatmentA survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunitiesEfficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Predictors of response to methotrexate in juvenile idiopathic arthritis.Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritisNutritional supplementation and dietary restriction in the resolution of enthesitis-related arthritis.Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.The development and assessment of biological treatments for children.A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors.Current medical treatments for juvenile idiopathic arthritis.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.Juvenile spondyloarthritis.Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatmentBiological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvementEtanercept treatment in juvenile idiopathic arthritis: the Polish registryFactors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept CohortAttainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active diseaseRecent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritisThe risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.Challenges in the management of juvenile idiopathic arthritis with etanerceptMedically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort StudyComparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanerceptUpdate on juvenile spondyloarthritis.Clinical utility of etanercept in the treatment of arthritides in children and adolescents.Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.Emerging drugs to treat juvenile idiopathic arthritis.Update on biologicals for treatment of juvenile idiopathic arthritis.Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis.Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.Etanercept: a review of its use in autoimmune inflammatory diseases.
P2860
Q26825309-0B08CB30-F7F2-4A71-B06B-13B56B212FFEQ26849497-DC27FCE1-F862-4F1F-A6AD-6A835EA6853BQ26995394-01B5B3FC-7F75-4E6C-BBE5-68502B11F3F5Q28079246-0590ACAE-4551-49D5-9B65-85167938E10FQ33576975-E0B78784-3124-403E-B533-DE542458B7BBQ33659233-8429761B-B9D4-47C8-85A2-5A2E17A52D8BQ33765738-542DAB5D-7577-4D31-A88E-EEF15E4107D9Q34069374-ADEE69FE-121B-46AF-B30A-B207691FA4B3Q34196943-63F5971B-4975-4637-ADF0-016CFB8CFE19Q34885098-D869B54E-3067-45CA-A159-2FF2FD349B0CQ34904542-690702FF-F25D-4D58-BAA4-61E4942BCF3DQ35112757-A1AB3829-65D7-4023-8FEA-B49BE8BF6815Q35135936-2C394BB0-212E-43D4-8BBC-49EC3CC06216Q35152199-4E7707B6-F4D0-4ACD-89D3-145E377E07EFQ35294398-11841212-C04C-4268-B337-E0FEE8B5FC2AQ35567870-5EDFE403-1B22-44B2-8E24-27079E1ACE5DQ35635172-6A8C19CA-2EA0-4A98-9CF4-68496A005FBFQ35800954-A13363EA-002F-4315-83C2-A63791ADC8B5Q36131029-D84359BD-5AA7-4025-BCBF-E2BF6D63E154Q36183846-F738CD33-9E74-4600-A77E-BB2E85312C0FQ36633259-44B123E0-C160-4044-844F-60CC5B2A3AD9Q36771435-4D6F6A41-1F6C-4E28-82E9-0A430568502DQ36795982-E71900E6-8E92-49D4-AB95-35A7A6FF406BQ37133996-34B0412E-56EA-43C6-AE00-6F75A8E27D46Q37207120-B9CF78FF-E436-4BDF-B074-D8F4E231E7FAQ37274470-B93CD0C4-CEFA-4723-84D9-C9F43192657BQ37303219-C27778BC-6002-467D-B5C5-3EA2D852D21DQ37308992-A7815E88-2B41-4B1F-B337-BCC69973BD2DQ37436386-88582AC2-20D5-4E4C-BF2C-DED9AF32F2A9Q37463702-0ADC2B85-33CD-4773-93D3-1525B3AC2AB0Q37518319-6C01AFAA-0B8E-47EF-879B-949744B90397Q37598921-7CDDDD97-FAE2-421F-8195-10F5B5400A1DQ37676020-2FC49127-E140-45DD-8ADE-9FCF55369D0BQ37866288-52C6CDD2-62F6-4D47-ABCB-5915D5725CC6Q37870209-28746FE5-8091-4F62-8F78-682DBA8F9284Q38071693-CD2BD2E4-5402-4B11-8962-02E7E413662AQ38087694-608B7D48-2FDB-4A58-9543-B9C053331BC0Q38092899-726DB1B1-6143-4E49-8C53-0AF24F22B16FQ38144094-B707D28C-195C-4856-97FA-0FF0E6A72DA7Q38230740-5B602818-3F9F-46AE-BAF5-8724FCFFA589
P2860
Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Safety and efficacy of combina ...... from the German JIA Registry.
@ast
Safety and efficacy of combina ...... from the German JIA Registry.
@en
type
label
Safety and efficacy of combina ...... from the German JIA Registry.
@ast
Safety and efficacy of combina ...... from the German JIA Registry.
@en
prefLabel
Safety and efficacy of combina ...... from the German JIA Registry.
@ast
Safety and efficacy of combina ...... from the German JIA Registry.
@en
P2093
P921
P356
P1476
Safety and efficacy of combina ...... from the German JIA Registry.
@en
P2093
German and Austrian Paediatric Rheumatology Collaborative Study Group
H J Girschick
H Schmeling
I Foeldvari
P304
P356
10.1136/ARD.2007.087593
P407
P577
2008-04-15T00:00:00Z